Morningstar

Zymeworks Inc Registered Shs ZYME

Stock XNAS Rating as of Oct 23, 2026

News

Zymeworks, Roche Enter Collaboration to Develop Experimental Lung Cancer Drug

Global News Select Oct 23, 2026, 10:54:00 AM
Zymeworks Enters into an Exclusive Global License and Collaboration Agreement with Roche for ZW209, a Trispecific T cell Engager Targeting DLL3

GlobeNewswire Oct 23, 2026, 10:00:00 AM
Zymeworks Appoints Suzanne Monahan as Senior Vice President, Commercial and General Manager, Theravance Biopharma

GlobeNewswire Oct 19, 2026, 10:00:00 AM
Zymeworks Announces Participation in Upcoming Investor Conferences and Date of Third Quarter 2026 Financial Results

GlobeNewswire Oct 15, 2026, 10:00:00 AM
Zymeworks Announces Updated 2026 Financial Guidance and Final Transaction Details Following Theravance Biopharma Acquisition

GlobeNewswire Sep 28, 2026, 10:00:00 AM
Zymeworks Completes Acquisition of Theravance Biopharma

GlobeNewswire Sep 23, 2026, 8:01:00 PM
U.S. FDA Approves Ziihera® (zanidatamab-hrii) with and without Tislelizumab plus Chemotherapy in First-Line HER2+ Advanced Gastroesophageal Adenocarcinoma

GlobeNewswire Aug 25, 2026, 2:23:13 PM
Zymeworks Announces Participation in Upcoming Investor Conferences

GlobeNewswire Aug 11, 2026, 10:00:00 AM
Zymeworks Provides Corporate Update and Reports Second Quarter 2026 Financial Results

GlobeNewswire Aug 6, 2026, 8:05:00 PM
Zymeworks Gets FDA Fast-Track Designation for ZW191 in Ovarian Cancer

Global News Select Mar 30, 2026, 10:32:00 AM
Zymeworks, Jazz Pharmaceuticals Shares Rise Following Positive Phase 3 Results for Cancer Treatment

Global News Select Nov 17, 2025, 12:16:00 PM

Sponsor Center

Transparency is our policy. Learn how it impacts everything we do

Transparency is how we protect the integrity of our work and keep empowering investors to achieve their goals and dreams. And we have unwavering standards for how we keep that integrity intact, from our research and data to our policies on content and your personal data.

We’d like to share more about how we work and what drives our day-to-day business.

How we make money

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions. Our investment management business generates asset-based fees, which are calculated as a percentage of assets under management. We also sell both admissions and sponsorship packages for our investment conferences and advertising on our websites and newsletters.

How we use your personal data

How we use your information depends on the product and service that you use and your relationship with us. We may use it to:

Verify your identity, personalize the content you receive, or create and administer your account.
Provide specific products and services to you, such as portfolio management or data aggregation.
Develop and improve features of our offerings.
Gear advertisements and other marketing efforts towards your interests.

To learn more about how we handle and protect your data, visit our privacy center.

How we approach editorial content

Maintaining independence and editorial freedom is essential to our mission of empowering investor success. We provide a platform for our authors to report on investments fairly, accurately, and from the investor’s point of view. We also respect individual opinions––they represent the unvarnished thinking of our people and exacting analysis of our research processes. Our authors can publish views that we may or may not agree with, but they show their work, distinguish facts from opinions, and make sure their analysis is clear and in no way misleading or deceptive.

To further protect the integrity of our editorial content, we keep a strict separation between our sales teams and authors to remove any pressure or influence on our analyses and research.

Read our editorial policy to learn more about our process.

© Copyright 2026 Morningstar, Inc. All rights reserved. Dow Jones Industrial Average, S&P 500, Nasdaq, and Morningstar Index (Market Barometer) quotes are real-time.